Search

Search articles for

Advanced filters

Published AfterYearMonthDay

Published BeforeYearMonthDay

By Author

By Section

By Issue

Search Results

##search.searchResults.foundPlural##

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

13-09-2023

https://doi.org/10.4081/dr.2023.9839

2858

PDF: 1015

HTML: 39
Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

Paolo Dapavo, Matteo Megna, Marina Talamonti

09-08-2024

https://doi.org/10.4081/dr.2024.9999

1850

PDF: 745

HTML: 109
Natural language processing of online support group postings reveals patients’ perspectives on strategies for managing psoriasis

Karan Rajalingam, Phillip M. Johansen, Nicole J. Levin, Jerry Qi, Oge Marques

11-09-2023

https://doi.org/10.4081/dr.2023.9824

1007

PDF: 977

HTML: 41
Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

Vasiliki Tasouli-Drakou, May Nguyen, Hannah Guinn, Omron Hassan, Sneha Butala, Sheshanna Phan

21-11-2022

https://doi.org/10.4081/dr.2022.9492

1828

PDF: 702

HTML: 92
Treatment satisfaction among patients with psoriasis in Saudi Arabia

Mahdi Aldhafiri, Rahaf Almutairi, Reem Albejais, Asma Almubark, Hussain Alwesaibie, Mohammed Albesher, Manayer Almustihi

15-04-2024

https://doi.org/10.4081/dr.2024.9967

1131

PDF: 647

HTML: 51
Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

12-11-2024

https://doi.org/10.4081/dr.2024.10080

1374

PDF: 750

HTML: 47
Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

11-11-2024

https://doi.org/10.4081/dr.2024.10140

1093

PDF: 579

SUPPLEMENTARY MATERIAL: 188

HTML: 24
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

19-05-2023

https://doi.org/10.4081/dr.2023.9692

1168

PDF: 576

HTML: 28
Atopic dermatitis: a brief review of recent advances in its management

Sultan Daghafak Alenazi

23-05-2023

https://doi.org/10.4081/dr.2023.9678

2518

PDF: 1454

HTML: 128
Domain-specific Skindex-29 response under biologics, conventional systemics, and phototherapy: a four-time-point real-world brief report

Ardea Milidrag, Milena Zlatanović, Vesna Miličić, Gordana Ristić, Kristina Andrić, Ana Ravić-Nikolić

22-09-2026

https://doi.org/10.4081/dr.2026.10651

86

PDF: 70
Hidradenitis suppurativa: state-of-the-art review and update

Marco Virone, Elena Zappia, Alberto Di Caro, Davide Carlesimo, Nicoletta Bernardini, Giovanni Pellacani, Antonio Giovanni Richetta, Steven Paul Nisticò, Annunziata Dattola

27-08-2025

https://doi.org/10.4081/dr.2025.10328

1330

PDF: 849

HTML: 17
Erythrodermic psoriasis improved by tildrakizumab

Giampaolo Trevisan, Lerica Germi, Luigi Naldi

23-11-2022

https://doi.org/10.4081/dr.2022.9448

1365

PDF: 642

HTML: 28
Late reaction to ustekinumab infusion

Marina Resener Morais, Luana Pizarro Meneghello, Carina Flores de Oliveira, André Vicente Esteves Carvalho

e2

09-09-2013

https://doi.org/10.4081/dr.2013.e2

4001

PDF: 693

HTML: 270
Certolizumab to treat hidradenitis suppurativa

Asem Shadid, Saud Alobaida, Yousef Binamer

27-10-2022

https://doi.org/10.4081/dr.2022.9566

1983

PDF: 758

HTML: 54
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

17-03-2022

https://doi.org/10.4081/dr.2022.9282

1230

PDF: 865

HTML: 49
Nightmares caused by isotretinoin in treating hidradenitis suppurativa: a case report and clinical insights

Fawaz Aljehani, Shumukh Alqahtani, Sara Alharbi, Seham Alsulami

06-12-2024

https://doi.org/10.4081/dr.2024.10171

1857

PDF: 490

HTML: 57
Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi

14-03-2022

https://doi.org/10.4081/dr.2022.9091

2668

PDF: 658

HTML: 16
Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

Martina Vispi, Teresa Corradin, Camilla Peccianti, Luca Feci, Laura Casini, Chiara Pisani, Susanna Fabbroni, Paola Corsetti, Margherita Croatto, Michele Pellegrino

25-06-2020

https://doi.org/10.4081/dr.2020.8642

1422

PDF: 776

HTML: 19
Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

Dimitris Rigopoulos, Aikaterini Patsatsi, Christina Antoniou, Dimitrios Sotiriadis, Angeliki Roussaki-Schulze, Nadia Boubouchairopoulou, Ioannis Skiadas, Vasillios Tsekouras, Ana Cristina Hernandez Daly

21-11-2022

https://doi.org/10.4081/dr.2022.9265

1582

PDF: 474

HTML: 37
Erythrodermic psoriasis treated with apremilast

John Arcilla, Daniel Joe, Johnathan Kim, Yohanan Kim, VuAnh N. Truong, Navin Jaipaul

19-09-2016

https://doi.org/10.4081/dr.2016.6599

2218

PDF: 992

HTML: 613
A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain

Judit Riera-Arnau, Daniel Wang, Jordi Mollet, Lucía Bellas, Ricardo Boy, Carlos González-Cruz, Mònica Sabaté, Elena Ballarín, Vicenç García-Patos, Glòria Aparicio

23-06-2026

https://doi.org/10.4081/dr.2026.10247

896

PDF: 321

SUPPLEMENTARY MATERIAL: 121
Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

30-07-2025

https://doi.org/10.4081/dr.2025.10379

576

PDF: 394

HTML: 15
Refractory pityriasis rubra pilaris treated with abrocitinib

Filip Rob

09-01-2025

https://doi.org/10.4081/dr.2025.10105

514

PDF: 327

HTML: 25
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks

Luciano Ibba, Luigi Gargiulo, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

06-06-2023

https://doi.org/10.4081/dr.2023.9722

854

PDF: 488

HTML: 27
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory markers in psoriasis: a case-control study

Hao Trong Nguyen, Long Dinh Hoang Vo, Nguyen Nhat Pham

14-07-2022

https://doi.org/10.4081/dr.2022.9516

1762

PDF: 755

HTML: 29

1 - 25 of 51 items 1 2 3 > >>

Search

Search Results

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

Natural language processing of online support group postings reveals patients’ perspectives on strategies for managing psoriasis

Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

Treatment satisfaction among patients with psoriasis in Saudi Arabia

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

Atopic dermatitis: a brief review of recent advances in its management

Domain-specific Skindex-29 response under biologics, conventional systemics, and phototherapy: a four-time-point real-world brief report

Hidradenitis suppurativa: state-of-the-art review and update

Erythrodermic psoriasis improved by tildrakizumab

Late reaction to ustekinumab infusion

Certolizumab to treat hidradenitis suppurativa

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Nightmares caused by isotretinoin in treating hidradenitis suppurativa: a case report and clinical insights

Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

Erythrodermic psoriasis treated with apremilast

A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain

Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Refractory pityriasis rubra pilaris treated with abrocitinib

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory markers in psoriasis: a case-control study

authors

reviewers

Categories

indexing

dermatopathology